Cabozantinib Fumarate is a selective multi-kinase inhibitor that targets receptors such as MET and VEGFR, and it is clinically indicated for the treatment of advanced renal cell carcinoma, hepatocellular… Read more
Cabozantinib Fumarate is a selective multi-kinase inhibitor that targets receptors such as MET and VEGFR, and it is clinically indicated for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, and medullary thyroid cancer. This category contains high-quality reference standards of Cabozantinib Fumarate API, along with essential pharmacopeial and non-pharmacopeial impurities, degradation products, and stable isotope labelled compounds. These materials are critical for laboratories conducting comprehensive impurity profiling and rigorous analytical method validation. By utilizing these characterized standards, researchers can ensure accurate identification and quantification of impurities during pharmaceutical development and ongoing quality control processes. Accessing reliable, traceable reference materials is a vital step in maintaining regulatory compliance and ensuring the consistency of therapeutic drug products throughout their lifecycle.